AU613009B2 - 4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid - Google Patents
4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid Download PDFInfo
- Publication number
- AU613009B2 AU613009B2 AU11758/88A AU1175888A AU613009B2 AU 613009 B2 AU613009 B2 AU 613009B2 AU 11758/88 A AU11758/88 A AU 11758/88A AU 1175888 A AU1175888 A AU 1175888A AU 613009 B2 AU613009 B2 AU 613009B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- subject
- salt
- monohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- VZXMZMJSGLFKQI-UHFFFAOYSA-N 4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CC=CP(O)(O)=O)CCN1 VZXMZMJSGLFKQI-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 89
- 238000011282 treatment Methods 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 23
- 150000004682 monohydrates Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 206010020852 Hypertonia Diseases 0.000 claims description 5
- 208000009205 Tinnitus Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 230000003412 degenerative effect Effects 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 231100000886 tinnitus Toxicity 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VZXMZMJSGLFKQI-ORCRQEGFSA-N 4-[(e)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(C\C=C\P(O)(O)=O)CCN1 VZXMZMJSGLFKQI-ORCRQEGFSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000011575 calcium Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- -1 4-substituted 2-piperazinecarboxylic acids Chemical class 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 210000003657 middle cerebral artery Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 229940102223 injectable solution Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 108091002531 OF-1 protein Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960004873 levomenthol Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000006884 silylation reaction Methods 0.000 description 2
- 239000012439 solid excipient Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VUBQHWMSZZVKHB-UHFFFAOYSA-N 3-bromoprop-1-en-2-ylphosphonic acid Chemical compound BrCC(=C)P(O)(O)=O VUBQHWMSZZVKHB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930182846 D-asparagine Natural products 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 241001106476 Violaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- AABMFMDCXOIAEY-UHFFFAOYSA-J potassium trisodium dihydrogen phosphate chloride hydroxide Chemical compound [Cl-].[Na+].P(=O)(O)(O)[O-].[K+].P(=O)(O)(O)[O-].[Na+].[OH-].[Na+] AABMFMDCXOIAEY-UHFFFAOYSA-J 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000026234 pro-estrus Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000009153 reflex inhibition Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
lr Mm!l CO0HMMONMWE A LTH 6OFASTLA A U S T R A L I A PATENT ACT 1952 COMPLETE SPECIFICATION
(ORIGINAL)
FOR OFFICE USE 613009 CLASS INT. CLASS Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority: Related Art-:
I
I
NAME OF APPLICANT: SANDOZ LTD.
ADDRESS OF APPLICANT: CH-4002 Basle, Switzerland.
a a NAME(S) OF INVENTOR(S) Bernhard AEBISCHER ADDRESS FOR SERVICE: DAVIES COLLISO4, Patent Attorneys 1 Little Collins Street, Melbourne, 3000.
'COMPLETE SPECIFICATION FOR THE INVENTION ENTITLED: 4-(3-Phosphono- 2-propenyl)-2-piperazinecarboxylic acid,, The following statement is a full description of this invention.' t.ncluding the best method of performing it known to us-
-I-
1 A Case 500-5719 4- (3-PHOSPHONO-2-PROPENYL)-2-PIPERAZINECARBQXYLIC ACID I *1
I.
4
I
I..
S
I
UK-Patent Application 2 157 685 describes 4-substituted 2-piperazinecarboxylic acids which have activity on the central nervous system.
It has'been found that one compound of this class, which has riot up until now toeen disclosed, has particularly strong activity on the central nervous system, is well tolerated and has long-lasting activity.
The present invention relates to £R-(E)]-4-(3-phosphono-2-propenyl)-2piperazinecarboxylic acid of formula I,I
I
0gII 0* S. I
I.
S
I
0* 5 0
S.
A
0S*S SO
S
OH
I
N I H 'COOH -r -L I
I~
2 500-5719 its pharmaceutically acceptable salts, a process for its production, pharmaceutical compositions contdining it and its use as a pharmaceutical.
The compound of formula I may be prepared by dealkylating a compound of formula II, 0
OR
OR
r R
COOH.
wherein R is (Ci-4)alkyl or aryl(C1-4)alky1.
The process can be carried out in known manner. For example the dealkylation can be effected by silylation followed by hydrolysis of the resulting silyl ester. Silylation can be performed with e.g.
bromotrimethylsilane in an organic solvent such as dichloromethane or chloroform at room temperature. The subsequent hydrolysis can i be effected under mild conditions.
When R is aryl(C 1 -4)alkyl, aryl is suitably an optionally substituted phenyl group, wherein suitable substituents include lower alkyl or lower alkoxy groups.
The compound of formula I including its salts, can also be obtained in the form of its hydrates, particularly the monohydrate. The hydrates, particularly the monohydrate, also form part of the invention.
f- I -3- 500-5719 The compound of formula II can be prepared as shown in the following reaction scheme:
CH
2 C 6
H
5
CH
2
C
6
H
5 1) (-)-menthol 2) separation of diastereoisomers
CH
2
C
6
H
N CHJCH N N
CH
2 CHSfhh CHI CH 3 Pd/C 3 0 0 0* 0 0 0.
0 0 00 0 0
OR
P
O
H CH
CH
N C 3
C
3 C I H coh o 4(
'COO
CH
5 3 (C2H5)3N BC 13 .00.
0 0
CH
3
CH
N C 3 H "Coo CH 3 1 I 4 500-5719 The compound of formula I may form cationic and acid addition salts.
Such salts are readily prepared by standard methods. Cationic salts include, but are not limited to, ammonium, sodium, potassium, calcium, piperidinium, morpholinium or pyrrolidinium salts. Acid addition salts include, but are not limited to, those formed with hydrochloric, hydrobromic, sulfuric, methanesulfonic, benzenesulfonic, p-toluenesulfonic and trifluoroacetic acid.
'he hydrate, especially the monohydrate of the compound of formula I has particularly interesting physico-chemical and other properties, e,g. as regards solubility, easy purification and stability. The hydrate may be obtained by crystallising the compound of formula I *from an aqueous medium, e.g. as described in Example e.g. from water/methanol In the following examples all temperatures are given in degrees centigrade and are uncorrected. The Ca]2D values are also uncorrected.
6 *6 *6 4 o *6 ~-111 II~ 5 500-5719 Example: [R-(E)]-4-(3-Phosphono-2-propenyl)-2-piperazinecarboxylic acid a) (R)-1,4-Bis(phenylmethyl)-2-piperazinecarhoxylic acid (1R, 2S, 5R)-5-methyl-2-(l-1ethyl ethyl)cyclohexyl ester To a solution of 761 g 1,4-dihenzyl-2-piperazinecarhoxylic acid ethyl ester (prepared according to E. Jucker and E. Rissi, Helv.
Chim. Acta 45 (1962) 2383) and 458 g (-)-menthol are added at g NaH (55%-60% dispersion) and 1 1 toluene. About 700 ml of the solvent are then slowly removed by destillation and continuously replaced by new portions of toluene (the reaction is monitored by TLC, ethylacetate/hexane The mixture is cooled to room temperature, treated with 1.25 1 2N aq. HC1 and 6 1 diethyl ether I and stirred thoroughly for 1 hour. The cristalline precipitate is filtered off and washed with diethyl ether and 0.1N aq. HC1. The S crude product is recrystallised from ethanol/0.2N aq. HC1, whereby the hydrochloride hydrate of the title compound, Ca]0 +18.5* (c 1.2 in CHC13) is obtained, which is used without further purification in the next step.
b) (R-:2-Piperazinecarboxylicacid_ 1R, _2S,_5R)-5methyl-2-(1 methylethyl)cyclohexyl ester 210 g of the product of step a) in 2 1 ethanol and 10.5 g Pd/C are hydrogenated 7 hours at room temperature and normal pressure, then filtered and evaporated in vacuum. The residue is treated with ethanolic HCI, the precipitate filtered and washed with ethanol/diethyl ether The product is recrystallised from water/methanol/ethylacetate to give the dihydrochloride of the title compound, m.p. 225-226', Ca] 20 -52.0' (c 1.34 in water). The dihydrochloride is treated with diethylether/ aq. ammonia, the organic phase is evaporated to dryness to give 6 500-5719 the title compound, m.p. 50-52', [a]2D -56.7' (c 1.05 in CHC13).
c) CR-(E)J-4-(3-Oiethoxyphosphinyl-2-propenyl)-2-piperazinecarboxylic acid 1 R, 2S, 5R)-5-methyl-2-( l -methylethyl)cyclohexyl ester To a stirred solution of 11.3 g of the free base of step b) and 5.9 ml triethylamine in 90 ml tetrahydrofuran are added at within 30 minutes 10.7 g 3-bromo-propen-2-yl-phosphonic acid dietnyl ester (prepared according to K. Hemmi, H. Takeno, M. Hashimoto and T. Kamiya, Chem. Pharm. Bull 30 (1982), 111) in ml tetrahydrofuran. Stirring is continued at -25' for hours. After filtration of the precipitate, the solution is concentrated at reduced pressure and the resulting syrup is chromatographed on silica gel using dichloromethane with addition of an increasing concentration of a 1:19 conc. aq. ammonia/ethanol mixture reaching 10% after 2 hours. The fraction eluted with dichloromethane/conc. aq. ammonia/ethanol 200:1:19 (rf 0.35) is isolated and concentrated in vacuum to give the title compound as an oil, [a] 2 0 -56.0* (c 1.3 in 2N aq. HC1). By treating the
D
product with ethanolic HCI/ether, the dihydrochloride is obtained, m.p. 157-163', Ca] 20 -48.2' (c 1.4 in 2N HC1).
So d) [R-(E1:-4-(3-Diethoxyphosphinyl-2-propenyl)-2-piperazinecarboxylic acid S 0* To a stirred solution of 5.79 g of the product of step c) in 58 ml abs. CH 2 C12 are added at -30' within 30 minutes 22.8 ml of a solution of boron trichloride in 1,2-dichloroethane (about 2.2 The reaction mixture is stirred 1 hour at -25' and 31 hours at At 0' 50 ml water are added and the mixture is neutralized by addition of 2N aq. NaOH and partitioned between H 2 0 f
CI.~
llr 7 500-5719 and CH 2 C12. The aqueous phase is evaporated to dryness in vacuum, the residue taken up in CHC13, filtered, dried (Na2S0 4 and evaporated to dryness in vacuum to give the title compound, which is used without further purification in the next step.
An analytical sample is purified by HPLC (Nucleosil RP-8, H20/CH30H 3 2) to give a foam Ca]0 18.0 (c 1.1 in N HC1).
360 MHz !H-NMR (DMSO, 150 OC): 1.24 (6H, t, J 7.0 Hz), 2.26 (1H, dxdxd, J 11.3 x 9.0 x 3.3 Hz), 2.35 (1H, dxd, J 11.3 x 8.6 Hz), 2.52 2.58 (1H, m), 2.77 (1i, dxdxd, J 12.1 x 9.0 x 3.3 Hz), 2.83 (1H, dxdxd, J 11.3 x 3.3 x 1.7 Hz), 2.99 (1H, dxt, J 12.1 x 3.9 Hz), 3.10 3.15 (2H, 3.33 (1H, dxd, J 8.6 x 3.3 Hz), 3.97 (4H, dxq, J 8.6 x 7.0 Hz), 5.50 (2H, broad), 5.88 (1H, dxdxt, J 21.5 x 17.1 x 2,1 Hz), 6.52 (1H, dxdxt, J 22.0 x 17.1 x 5.6 Hz), e) CR-(E)]-4-(3-Phosphono-2-propenyl)-2-piperaznecarboxylic acid 3.9 g of the crude compound of step d) are dissolved in 300 ml abs. CH2C12, treated at room temperature with 9.6 ml bromotrimethylsilane and stirred for 16 hours. The reaction mi.xture is evaporated, the residue taken up in H20, stirred for 1 hour and filtered. The pH of the solution is adjusted to 6 by addition of Dowex 1x4 (OH-form) and the mixture is placed on the top of a column containing Dowex 1x4 (acetate form). Elution with a gradient of aqueous acetic acid (0.05 to 0.25 N) gives a foam on concentration to dryness in vacuum. The foam is crystallized from H20/CH30H and recrystallized from H20/C2H50H to give the title 0 compound as the monohydrate, m.p. 2060 (decomposition). [a) 0 -21,6 (c 1.1 in 2N HCI). The absolute configuration is deduced by a chemical correlation with D-asparagine and confirmed by an X-ray structure analysis, r 8 500-5719 The compound of formula I exhibits valuable pharmacological activity and is, therefore, indicated for use as a pharmaceutical, e.g.
for therapy. In particular, the compound possess luteinising hormone (LH) and testosterone secretion inhibiting activity in the following test: Adult male rats of the Wistar strain (SIV, Kissleg, West Germany, 200-300 g) receive the test compound intraperitoneally. 2 hours later the rats are killed by decapitation and blood samples are taken. Serum LH is measured using a bioassay based on the production of testosterone by disperse, collagenase treated rat interstitial Leydig cells exposed to LH containing serum or rat LH-standard; serum testosterone is measured by radioimmunoassay (125-J-T, cis, Medipro Teufen, Switzerland) [cf. E, del Pozo, A. Podesta, A. Solano, J. Calaf, M. Mark6, in Biorhythms and Stress in the Physiopathology Sof Reproduction, P. Pancherl and L. Zichella (Eds), Hemisphere Publishing Co. Washington, 389-398 (1988)].
The compound of formula I inhibits LH- and testosterone-secretion at the dose of 3.2 mg/kg i.p. significantly. (*)-4-(3-Phosphono-2-propenyl)-2-piperazinecarboxylic acid (hereinafter called CPP-ene), the corresponding racemate of the compound of formula I, at 3.2 mg/kg i.p.
has no effect on LH-secretion and only weakly inhibits testosteronesecretion.
In female rats the compound of formula I inhibits LH-dependent spontaneous ovulation in the following test [cf. M. Markb and E. Fluckiger, Neuroendocrinology 30,* 228-231 (1980)]: Female rats of the Wistar strain (SIV, Kissleg, West Germany, 200-300 g) with regular 4 day cycles receive the test substance during proestrus at 13.00 and 15.00 hrs. intraperitoneally. The next day at 9.00 h, when the rats are in estrus, they are sacrified, the oviducts examined 9 500-5719 *0 40 0 06
S
0t 9 *i 5 0*; 00r microscopically and the ova counted. Ovulation is deemed to be inhibited only if no ova counted. The compound of formula I (tested as the monohydrate) inhibits spontaneous ovulation significantly when administered at dosages of 2 x 3.2 mg/kg i.p. (at 13.00 3.2 mg/kg i,p.
and at 15.00 h 3.2 mg/kg CPP-ene inhibits spontaneous olation very weakly when administered at dosages of 2 x 3.2 mg/kg i.p.
under the same experimental conditions.
The compound of formula I is, therefore, indicated for use in the treatment of disorders having an aetiology associated with or modulated by LH secretion or having an aetiology in which the physiological regulation of LH secretion is implicated, for example in the treatment of prostate hypertrophy, in the treatment of menopausal syndrome, as well as the treatment of mammary- and prostate-carcinoma, For this use an indicated daily dosage is in the range from about 1 to about 800 mg of the compound conveniently given in divided doses 2 to 4 times a day in unit dosage form containing for example from about 0.25 to about 400 mg of the compound or in sustained release form.
The compound of formula I shows muscle relaxant activity in the conscious rabbit in dosages from 0.01 to 0.05 mg/kg i.v.
Teschendorf et al., Arch. Exp. Pharmacol. 266, 467-468 (1970)].
In this test the monohydrate of the compound of formula I causes a inhibition of reflex muscle tone after administration of 0.02 mg/kg whereas CPP-ene inhibits reflex muscle tone by 47% after administration of 0.5 mg/kg the compound of formula I being about 25 times more active than the corresponding racemate.
The compound of formula I is, therefore, indicated for use in the treatment of increased muscle tone, for example in the treatment of painful muscle spasms attributable to static and functional I t-- 10 500-5719 disorders of the lumbar or cervical spine or after surgery or in the treatment of spasticity, e.g. due to multiple sclerosis, diseases of the spinal cord, cerebrovascular accidents, cerebral trauma or cerebral palsy. For this use an indicated daily dosage is in the range from about 1 to about 800 mg of the compound conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing for example from about 0.25 to about 400 mg of the compound or in sustained release form, a Furthermore, the compound of formula I red,'ces ischaemia-induced neuronal damage and ensuing symptoms in the middle cerebral artery (MCA) occlusion model in rats at a dosage of 1-30 mg/kg s.c. and particularly at 3 x 10 mg/kg i,p. [cf. A.Tamura et al,, J, Cereb, Blood Flow Metabol. 1, 53-60 (1981), A. Sauter, M. Rudin, Stroke 17, 1228-1234 (1986)], The area of infarcted tissue is measured using MCID image analysis software (developed by Imaging Research Inc.) in horizontal 20 pm thick slices sectioned at multiple levels and stained by cresyl violett. The total volume of brain showing ischaemic damage is estimated by adding the 5 areas obtained from the 5 slices, The infarct size determined histologically 5 days after occlusion of MCA is reduced by more than 20% after treatment with 3 x 10 mg/kg i,p. of the monohydrate of compound of formula I (first injection immediately after MCA occlusion, second and third after 8 respectively 16 hours).
11 500-5719 The compound is therefore indicated for use in the prophylaxis and therapy of conditions associated with cerebral ischaemia e.g. stroke.
For this use an indicated daily dosage is in the range from about to about 800 mg of the compound conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing for example from about 6 to about 400 mg of the compound or in sustained release form.
Furthermore, the compound of formula I has a potent, selective and competitive antagonistic action on NMDA (N-Methyl-D-aspartic acid) receptors. Thus the monohydrate of the compound of formula I inhibits NMDA-induced depolarisations in the isolated frog spinal cord assay P.L.Herrling, Neuroscience 14, 417-426 (1985)] with a pA 2 value of 6.8, CPP-ene with a pA 2 value of 6.2, thus the compound of formula I being about 4-fold as active as the corresponding racemate, CPP -3-(2-carboxypiperazin-4-yl)propyl-l-phosphonic acid], the emphasized compound of UK Patent Application 2 157 685 has a pA 2 value of 5,8.
In the NMDA-induced sodium efflux assay on rat brain slices (Luini A., Goldberg 0. Teichberg Proc. Natl. Acad. Sci. USA 78, 3250-3254 (1981)] the monohydrate of the compound of formula I has a pA 2 value of 6.5 and CPP-ene a pA 2 of 6,2, the compound of formula I being about twice as active as the corresponding racemate. CPP has a pA 2 value of 9 The selectivity of the NMDA antagonistic action is indicated in that it is inactive, as well as CPP-ene and CPP,in the quisqualate- and kainate-induced sodium efflux test up to a concentration of 1 mM.
As a result of its NMDA receptor antagonism the compound of formula I is indicated for use in the treatment of anxiety, schizophrenia and depression or of CNS degenerative disorders, such as Huntington's,
"T
1, I 9 6 9 'I 99 9 S S* 99* 9.* ;j @9 I i i 0 t e 12 500-5719 Alzheimer's or Parkinson's diseases. For these uses an indicated daily dosage is in the range from about 25 to about 800 mg of the compound conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing for example from about 6 to about 400 mg of the compound or in sustained release form.
As a result of its NMDA receptor antagonism the compound of formula I is further indicated for use in the treatment of tinnitus. For this use an indicated daily dosage is in the range from about 25 to about 800 mg of the compound conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing for example from about 6 to about 400 mg of the compound or in sustained release form.
Additionally the compound of formula I shows anticonvulsant activity in electroshock-induced convulsions in the mouse Swinyard, JAm. Pharm. Assoc. Scient, Ed. 38, 201 (1949) and J. Pharmacol.
Exptl. Therap. 106, 319 (1952)]. In this test, groups of 6 male mice (18-26 g, OF-1, Sandoz Basle) receive the test substance intraperitoneally. After 1, 2 and 4 hrs. a 50 mA, 200 ms long shock is applied via corneal electrodes, smeared with electrolyte jelly. This supra-maximal shock produces tonic extensor convulsions of all extremities, Inhibition of the hindlimb extension is taken as a protective action. After investigation of several dose-levels the threshold dose is estimated. The threshold dose at 1 hour, the dose required to inhibit the hindlimb extension is <1 mg/kg i.p. for the compound of formula I (monohydrate) and between 3-10 mg/kg i.p. for CPP-ene. The literature threshold dose of CPP is 10 mg/kg i.p.
I
13 500-5719 In the following table, the inhibition of hindlimb extension, expressed in is given for the compound of formula I in comnarison with the corresponding racemate: Dose mg/kg i.p.
Inhibition of E-shock induced hindlimb extension lh 2h 4h se 0 0 0 *r 0 00 41SS to Compound of formula I monohydrate 1 67* 67* 33 2.5 83* 83* 67* 3 100* 100* 83* CPP-ene 1 20 50 3 33 67* 17 67* 80* Fisher-Test, control vs. substance group, 0.05.
As can be seen from the table, the compound of formula I' has higher anticonvulsant activity than the corresponding racemate when tested against electroshock-induced convulsions in mice.
0 I i 'iina- 14 500-5719 The compound of formula I further inhibits N-Methyl-D-aspartic acid (NMDA) induced convulsions in the mouse. In this test groups of 6 female mice (18-26 g, OF-1, Sandoz Basle) were pretreated with the test substance intraperitoneally. 30 minutes later they are challenged with 400 mg/kg s.c. NMDA in the neck region and observed for minutes. The latencies for the appearance of the first signs of convulsions, for the first tonic convulsions and for the occurrence of death are noted. The significance of any differences is assessed using the Mann-Whitney U-test Siegel, Non-parametric Statistics, McGraw-Hill, New York 1956]. The threshold dose is the smallest dose Sat which there is a significant inhibition of convulsive symptoms.
The threshold dose of the compound of formula I (tested as monohydrate) is approximately 5 mg/kg of CPP 10 mg/kg i.p.
As a result of its anticonvulsant activity the compound of formula I is indicated for use in the treatment of epilepsy. For this use an indicated daily dosage is in the range from about 25 to about 800 mg of the compound conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing for example from about 6 to about 400 mg of the compound or in sustained release form.
The compound of formula I further shows analgesic activity in the isolated rat spinal cord-tail in vitro using capsaicin (0.8-1 AM) as a chemical noxious stimulus eliciting depolarising ventrl root responses Yanagisawa et al., European J. Pharmacol. 106,231-239 (1984)]. The monohydrate of the compound of formula I reduces the chemical stimulus by 75-80% at a concentration of 10 M.
The compound of formula I is, thereforeindicated for use for relieving pain. For this use an indicated daily dosage is in the range from about 25 to about 800 mg of the compound conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing :r i 15 500-5719 *r
S
*5 *5 St *r 0
S*
S* S
S
S.
for example from about 6 to about 400 mg of the compound or in sustained release form.
Moreover, the compound of formula I as well as the corresponding racemate have no effects on blood pressure and heart rate in the anaesthetised cat in a dose up to 10 mg/kg i.v. In pilot toxicity tests with dogs over 4 week's 3 mg/kg/day i.v. of. the compound of formula I are well tolerated.
As can be seen from the above test results, the strong LH secretion inhibiting activity, the marked (25 fold) increase of the muscle relaxant activity as well as the two- to four-fold NMDA receptor antagonistic activity of the compound of formula I as compared to the corresponding racemate is not accompanied by a similar increase in the side effects, e.g. cardiovascular effects.
The compound of formula I may 'be administered as such or as its pharmaceutically acceptable salts. Such salts exhibits the same order of activity as the compound of formula I.
S 59
S
16 500-5719 The present invention further provides pharmaceutical compositions comprising the compound of formula I or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or diluent.
The compound of formula I may be administered by any conventional route, in particular enterally, preferably orally or parenterally. The compound of formula I may be administered as such or admixed with convventional pharmaceutical carriers. For example, for oral administration e.g. in the form of tablets or capsules, the compound of formula I may be admixed with conventional pharmaceutically acceptable excipients, e.g. inert diluents, such as lactose, mannitol, calcium sulfate, microcristalline cellulose; disintegrating agents, e.g. starch, sodium carboxymethyl cellulose, sodium carboxymethyl starch, alginic acid, crospovidone; binding agents such as cellulose derivates (methyl-, hydrqxymethyl-, hydroxypropylmethyl-), povidone, gelatine; lubri- S* cating agents e.g. siliciumdioxide, stearic acid, magnesium or calcium .tearate; hydrogenated oils such as castor oil, glycerolesters e.g. palmitostearate' and/orflavouring, colouring and sweetening agents.
The tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. Parenteral compositions are preferably in the form of a sterile injectable aqueous solution. Such aqueous solutions should be suitably buffered if necessary and rendered isotonic with sufficient saline. Optionally a preservative, such as benzyl alcohol, can be added.
A unit dosage may contain from about 0.25 to about 400 mg of the compound of formula I or a pharmaceutically acceptable salt thereof.
The pharmaceutical compositions can be prepared according to conventional techniques.
T- 17 500-5719 For the manufacture of tablets, the compound of formula I can be mixed with lactose and granulated with water, 0.5% sodium alginate or hydroxypropylmethylcellulose solution. The dried granulate is compressed into tablets in the presence of about 20% of corn starch and 1% of magnesium stearate. In this way, there are obtained, e.g.
tablets of the following composition: S S* S S
S@
S
Ingredients Compound of formula I monohydrate Lactose Corn Starch Hydroxypropylmethylcellulose Magnesium stearate Siliciumdioxide Tablet Weight (mg) 97 2 1.
S.
55* S S 55* 0 0 55, S9* S S SeeS S* S These tablets, which are provided with a crackline, orally in a dosage of one haif to one tablet one to can be administered four times per day.
Capsules may contain the active agent alone or admixed with an inert solid excipient, for example as mentioned above.
Capsules containing the ingredients indicated below may be prepared by conventional techniques and are administered at a dose of one capsule 1 to 4 times a day.
'I.
18 500-5719 Ingredients Compound of formula I monohydrate Inert solid excipient (corn starch, lactose, aerosil, magnesium stearate) Similarly tablets and capsules containing 25 mg and compound of formula I may be prepared.
Capsule Weight (mg) 250 100 mg of the 5 0RS 0*
S
5 0 *5
S
*5 9 S.
0* The following injectable solution is formulated with the indicated amount of active agent using conventional techniques. The injectable solution is suitable for administration once a day.
Sterile.injectable solution Ingredients Compound of formula I monohydrate Sodium chloride Potassium dihydrogen phosphate Disodium hydrogen phosphate Benzyl alcohol Water for injection Weight (mg/ml) 3.63 .5.68 q.s. to 1 ml The solutions may be filtered through a 0.2 im sterile filter and aseptically filled in ampoules. The ampoules are gassed with carbon dioxide.
I i I I II 19 500-5719 The present invention also provides the compound of formula I or a pharmaceutically acceptable salt thereof for use as a pharmaceutical, e.g. for use in the treatment of disorders associated with LH secretion; treatment of increased muscle tone; treatment of conditions associated with cerebral ischaemia; treatment of anxiety, schizophrenia, depression or CNS degenerative disorders; treatment of tinnitus; treatment of epilepsy or relieving pain.
The present invention accordingly provides a method for the treatment of disorders associated with LH secretion; treatment of increased muscle tone; treatment of conditions associated with cerebral ischaemia; treatment of anxiety, schizophrenia, depression or CNS degenerative disorders; treatment of tinnitus; treatment of epilepsy or relieving pain in a subject which comprises administering a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof to a subject in need of 0* *0 such treatment.
The present invention further provides the compound of formula I or a pharmaceutically acceptable salt thereof for use in the manufacture of a pharmaceutical composition for use in the treatment of disorders associated with LH secretion, increased muscle tone, conditions associated with cerebral ischaemia, anxiety, schizophrenia, depression, CNS degenerative disorders, tinnitus or epilepsy or in relieving pain.
Claims (1)
- 500-5719 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A process for the production of [R-(E)]-4-(3-Phosphono-2- propenyl)-2-piperazinecarboxylic acid of formula 1, OH 0' H NZ H COOH S or a salt thereof, which comprises dealkylating- a compound of formula II, S. 0 I OR *H \COOH wherein R is (Ci.. 4 )alkyl or aryl(,Cl..4)alkyl, and optionally forming a salt thereof. 2. A process for the production of the compound of formula I or a salt thereof as hereinbefore described with reference to any of the Examples. I i lyi. i i 21 500-5719 3. Compound of formula I or a salt thereof whenever produced by process according to claim 1. 4. Compound of formula I or a salt thereof. Compound according to claim 4 in the form of its monohydrate or a salt thereof. 6. A method of treating conditions associated with cerebral ischaemia in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of the compound of formula I or the monohydrate or a pharmaceutically acceptable salt thereof. e 7. A method of treating anxiety in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of the compound of formula I or the monohydrate or a pharmaceutically acceptable salt thereof. 8. A method of treating epilepsy in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of the compound of formula I or the monohydrate or a pharmaceutically acceptable salt thereof. 9. A method of treating disorders associated with LH secretion or increased muscle tone or schizophrenia or depression or CNS degenerative disorders or tinnitus or relieving pain in a subject in need of such treatment, which comprises 1 -J Dr) w-- i I I i 4r 22 500-5719 administering to said subject a therapeutically effective amount of the compound of formula I or the monohydrate or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a compound as claimed in claim 4 or 5 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable diluent or carrier therefor. 11. A compound of formula I as defined in claim 1 or methods for its manufacture substantially as hereinbefore described with reference to the Example. DATED this 15th day of March, 1991 Sandoz Ltd. By Its Patent Attorneys DAVIES COLLISON 6 S. 6* 6 6e@ S 0S 6 *6 S O S *6056 *6 S ii Ar/B w^~e
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8703749 | 1987-02-18 | ||
GB878703749A GB8703749D0 (en) | 1987-02-18 | 1987-02-18 | Piperazinecarboxylic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1175888A AU1175888A (en) | 1988-08-25 |
AU613009B2 true AU613009B2 (en) | 1991-07-25 |
Family
ID=10612501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU11758/88A Ceased AU613009B2 (en) | 1987-02-18 | 1988-02-16 | 4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid |
Country Status (28)
Country | Link |
---|---|
JP (1) | JPH0723387B2 (en) |
KR (1) | KR960015190B1 (en) |
AT (1) | AT391320B (en) |
AU (1) | AU613009B2 (en) |
BE (1) | BE1002427A3 (en) |
CA (1) | CA1327799C (en) |
CH (1) | CH675125A5 (en) |
CY (1) | CY1739A (en) |
DE (1) | DE3804936C2 (en) |
DK (1) | DK168441B1 (en) |
ES (2) | ES2011319A6 (en) |
FI (1) | FI86733C (en) |
FR (1) | FR2610932B1 (en) |
GB (2) | GB8703749D0 (en) |
GR (1) | GR1002471B (en) |
HK (1) | HK142093A (en) |
HU (2) | HU199858B (en) |
IE (1) | IE59098B1 (en) |
IL (1) | IL85436A0 (en) |
IT (1) | IT1219447B (en) |
LU (1) | LU87129A1 (en) |
MY (1) | MY103206A (en) |
NL (1) | NL8800412A (en) |
NZ (1) | NZ223529A (en) |
PH (1) | PH25512A (en) |
PT (1) | PT86776B (en) |
SE (1) | SE467256B (en) |
ZA (1) | ZA881146B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU651125B2 (en) * | 1990-06-18 | 1994-07-14 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Treatment of mood disorders with functional antagonists of the glycine/NMDA receptor complex |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU202111B (en) * | 1988-03-11 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component |
EP0488959A3 (en) * | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
US5260286A (en) * | 1992-10-16 | 1993-11-09 | Japan Tobacco, Inc. | 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists |
AU5693996A (en) * | 1995-05-08 | 1996-11-29 | Lonza A.G. | Biotechnical production process of piperazine r-alpha-carbox ylic acids and piperazine s-alpha-carboxylic acid amide |
EA001904B1 (en) | 1997-05-12 | 2001-10-22 | ОРТО МакНЕЙЛ ФАРМАСЬЮТИКАЛ, ИНК. | Arylsubstituted piperazines useful in the treatment of bening prostatic hyperplasia |
GB9821179D0 (en) * | 1998-09-30 | 1998-11-25 | Merck Sharp & Dohme | Therapeutic use |
JP2008124531A (en) | 2006-11-08 | 2008-05-29 | Nec Electronics Corp | Semiconductor device and audio processor chip |
EP3427729A1 (en) | 2017-07-13 | 2019-01-16 | Paris Sciences et Lettres - Quartier Latin | Probenecid for use in treating epileptic diseases, disorders or conditions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2157685A (en) * | 1984-04-17 | 1985-10-30 | Nat Res Dev | Piperazine derivatives |
-
1987
- 1987-02-18 GB GB878703749A patent/GB8703749D0/en active Pending
-
1988
- 1988-02-11 LU LU87129A patent/LU87129A1/en unknown
- 1988-02-12 FR FR888801782A patent/FR2610932B1/en not_active Expired - Lifetime
- 1988-02-12 BE BE8800177A patent/BE1002427A3/en active
- 1988-02-12 IT IT47631/88A patent/IT1219447B/en active
- 1988-02-15 GB GB8803438A patent/GB2201676B/en not_active Expired - Lifetime
- 1988-02-15 MY MYPI88000155A patent/MY103206A/en unknown
- 1988-02-16 NZ NZ223529A patent/NZ223529A/en unknown
- 1988-02-16 PH PH36514A patent/PH25512A/en unknown
- 1988-02-16 IL IL85436A patent/IL85436A0/en not_active IP Right Cessation
- 1988-02-16 IE IE41388A patent/IE59098B1/en not_active IP Right Cessation
- 1988-02-16 CH CH549/88A patent/CH675125A5/de not_active IP Right Cessation
- 1988-02-16 AU AU11758/88A patent/AU613009B2/en not_active Ceased
- 1988-02-16 GR GR880100084A patent/GR1002471B/en not_active IP Right Cessation
- 1988-02-16 DK DK079688A patent/DK168441B1/en not_active IP Right Cessation
- 1988-02-16 HU HU88746A patent/HU199858B/en not_active IP Right Cessation
- 1988-02-16 CA CA000559170A patent/CA1327799C/en not_active Expired - Fee Related
- 1988-02-17 DE DE3804936A patent/DE3804936C2/en not_active Expired - Fee Related
- 1988-02-17 KR KR1019880001680A patent/KR960015190B1/en not_active IP Right Cessation
- 1988-02-17 AT AT0036788A patent/AT391320B/en not_active IP Right Cessation
- 1988-02-17 PT PT86776A patent/PT86776B/en not_active IP Right Cessation
- 1988-02-17 FI FI880744A patent/FI86733C/en not_active IP Right Cessation
- 1988-02-17 JP JP63036458A patent/JPH0723387B2/en not_active Expired - Lifetime
- 1988-02-17 SE SE8800541A patent/SE467256B/en not_active IP Right Cessation
- 1988-02-18 ZA ZA881146A patent/ZA881146B/en unknown
- 1988-02-18 ES ES888800466A patent/ES2011319A6/en not_active Expired - Lifetime
- 1988-02-18 NL NL8800412A patent/NL8800412A/en not_active Application Discontinuation
-
1989
- 1989-10-16 ES ES8903482A patent/ES2021904A6/en not_active Expired - Lifetime
-
1993
- 1993-12-30 HK HK1420/93A patent/HK142093A/en not_active IP Right Cessation
-
1995
- 1995-06-09 HU HU95P/P00176P patent/HU211269A9/en unknown
- 1995-10-20 CY CY173995A patent/CY1739A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2157685A (en) * | 1984-04-17 | 1985-10-30 | Nat Res Dev | Piperazine derivatives |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU651125B2 (en) * | 1990-06-18 | 1994-07-14 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Treatment of mood disorders with functional antagonists of the glycine/NMDA receptor complex |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS593988B2 (en) | Olefin derivatives of amino acids | |
JPH05320162A (en) | Peptidic quinuclidine | |
US6506753B2 (en) | Methods of making and using N-desmethylzopiclone | |
JPH07223953A (en) | Medical composition for curing disease of central nervous system | |
EP1100508A2 (en) | Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders | |
WO2004037212A2 (en) | Compositions comprising zopiclone derivatives and methods of making and using the same | |
AU613009B2 (en) | 4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid | |
WO1996029331A1 (en) | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation | |
WO2007117544A2 (en) | Carnitine conjugates of adamantanamines and neramexane derivatives as duel prodrugs for various uses | |
EP3822252A1 (en) | Composition of fused tricyclic gamma-amino acid derivative and preparation therefor | |
SK281085B6 (en) | 2-(aminomethyl)-3,4,7,9-tetrahydro-2h-pyrano-[2,3]-indol-8-ones and their derivatives, pharmaceutical composition containing them and their use | |
EP0085893A2 (en) | Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them | |
US4904670A (en) | Pyridine derivatives having anxiety state or sleep thereapeutic properties | |
WO2006029549A1 (en) | Quinuclidine compounds having quaternary ammonium group, it's preparation method and use as blocking agents of acetycholine | |
EP0573548B1 (en) | Neuroprotectant agents | |
JP3681770B2 (en) | Treatment for senile dementia or Alzheimer's disease | |
HU191795B (en) | Process for producing pyrrolizidine derivatives | |
GB2087889A (en) | Naphthyridine derivatives | |
RU2173146C2 (en) | Derivatives of polycyclic alkaloids as antagonists of nmda-receptors | |
PL153236B1 (en) | Method of obtaining piperazine carboxylic acid | |
JPH0710851A (en) | Aminoalcohol derivative and its use | |
JPH06234766A (en) | Optically active isoindolin derivative | |
DE19622734A1 (en) | New aminated hydroxy-alkynyl-xanthine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |